These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35295328)

  • 1. Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism.
    Xie L; Xiao Y; Tai S; Yang H; Zhou S; Zhou Z
    Front Pharmacol; 2022; 13():836849. PubMed ID: 35295328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus.
    Srinivas N; Sarnaik MK; Modi S; Pisipati Y; Vaidya S; Syed Gaggatur N; Sange AH; Sange I
    Cureus; 2021 Aug; 13(8):e16868. PubMed ID: 34513443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.
    Mondal S; Pramanik S; Khare VR; Fernandez CJ; Pappachan JM
    World J Cardiol; 2024 May; 16(5):240-259. PubMed ID: 38817648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.
    Aftab S; Vetrivel Suresh R; Sherali N; Daniyal M; Tsouklidis N
    Cureus; 2020 Oct; 12(10):e10783. PubMed ID: 33042651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
    Ala M
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients.
    Tilinca MC; Tiuca RA; Tilea I; Varga A
    J Pers Med; 2021 Nov; 11(12):. PubMed ID: 34945721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors.
    Chaurasia PP; Dholariya S; Kotadiya F; Bhavsar M
    Cureus; 2021 Sep; 13(9):e18300. PubMed ID: 34722075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
    Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
    Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms.
    Li W; Yu K; Sun S
    Pharmazie; 2020 Jun; 75(6):224-229. PubMed ID: 32539914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
    Asrih M; Gariani K
    Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.